31.08.2013 Views

Rivaroxaban for the treatment of deep vein thrombosis and ...

Rivaroxaban for the treatment of deep vein thrombosis and ...

Rivaroxaban for the treatment of deep vein thrombosis and ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

The manufacturer did not assume a reduction in QoL <strong>for</strong> patients experiencing a minor bleed event.<br />

Health state utility values <strong>and</strong> <strong>the</strong> duration used in <strong>the</strong> economic model are summarised in Table 29.<br />

Table 29: Health state utility values used in <strong>the</strong> cost-effectiveness evaluation<br />

(Adaptation from Table 46, p. 134, MS, 1 November 2011)<br />

Model state Point<br />

estimate<br />

Adjustments to<br />

utility norm due to<br />

modelled events<br />

111<br />

Source Duration<br />

Population norm 0.825 NA Kind 1998 66 NA<br />

Post IC bleed 0.71 NA Rivero-Arias 2010 67 Chronic<br />

CTEPH 0.56 NA Meads 2008 70 Chronic<br />

DVT 0.729 0.884 d Derived from Locadia<br />

et al. (2004) 68 <strong>and</strong><br />

Kind et al.(1998) 66<br />

1 month<br />

PE 0.547 0.663 1 month<br />

EC bleed 0.287 0.684 1 month<br />

IC bleed 0.564 0.347 3 months<br />

PTS 0.767 0.930 Derived from Lenert<br />

et al.(1997) 69 <strong>and</strong><br />

Kind et al.(1998) 66<br />

Chronic<br />

The utility decrements <strong>for</strong> patients experiencing a DVT, PE or a major EC bleed event was assumed<br />

to last a month in line with <strong>the</strong> assumption used in NICE CG92. 18 The utility decrement <strong>for</strong> patients<br />

with an IC bleed event was assumed to last three months. O<strong>the</strong>r events were assumed to be chronic.<br />

Finally, health state utility values were assumed to be constant over time, i.e. no variation by age.<br />

The ERG is generally satisfied with <strong>the</strong> assumptions made by <strong>the</strong> manufacturer to value <strong>the</strong> different<br />

health states. A systematic review <strong>of</strong> <strong>the</strong> literature was conducted to identify potential sources <strong>of</strong><br />

evidence <strong>and</strong> this appears to be <strong>of</strong> reasonable quality; however, <strong>the</strong> ERG did not replicate <strong>the</strong><br />

systematic review due to time <strong>and</strong> resource constraints. The manufacturer assumed that <strong>the</strong> utilities<br />

<strong>for</strong> <strong>the</strong> IC <strong>and</strong> EC bleed health states were identical to GI bleeds <strong>and</strong> haemorrhagic stroke<br />

respectively. The manufacturer also used data from different studies that used different methods to<br />

value <strong>the</strong> different health states. Whilst this is not very robust, <strong>the</strong> ERG acknowledges that all <strong>the</strong><br />

evidence was not available from one study, con<strong>for</strong>ming to <strong>the</strong> NICE reference case (using EQ-5D <strong>and</strong><br />

time trade <strong>of</strong>f estimated from <strong>the</strong> general population).<br />

d Locadia quoted a population norm (own health) as 0.95 (95% CI 0.81-1.00) <strong>and</strong> <strong>the</strong>re<strong>for</strong>e fur<strong>the</strong>r adjustment was applied to<br />

<strong>the</strong> values reported in <strong>the</strong> study, multiplying by 0.825/0.95<br />

Copyright 2012 Queen's Printer <strong>and</strong> Controller <strong>of</strong> HMSO. All rights reserved.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!